Call for abstracts

Abstracts submitted for presentation in the EORTC-NCI-AACR Symposium will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted. The final decision on the presentation format of all selected abstracts lies at the sole discretion of the Scientific Committee.

LBA SUBMISSION GUIDELINES
SUBMISSION GUIDELINES

Abstracts submitted after the stipulated deadline will not be considered.

Authors are strongly advised to submit prior to the deadline and avoid unnecessary delays which may affect the standing of their abstract.

In case of any abstract related queries please contact: pat.vanhove@eortc.org.

Submitting an abstract for presentation in the 36th EORTC-NCI-AACR symposium does not constitute registration for the event. When selected, abstract presenters must register to attend the 36th EORTC-NCI-AACR symposium.

The presenting author will receive the result of the review and the Scientific Committee’s decision on their abstract by email at the latest by end of August 2024.

Abstract Submission now closed. 

PLEASE NOTE: Titles will be released in the programme once the authors have been notified of acceptance of abstracts.
Unless they are part of the media programme, embargoed or not consented,  all abstracts will be released on 9 October 2024.
All other abstracts will be released on the day of presentation.

LBA SUBMISSION GUIDELINES
SUBMISSION GUIDELINES

Abstact Topics

  • Angiogenesis and vascular disrupting agents

  • Animal Models

  • Antibody-drug conjugates
  • Apoptosis inducers
  • Artificial Intelligence
  • Biomarkers Assays
  • Cancer Genomics
  • Cellular Therapies
  • Chemoprevention
  • Combination therapies
  • Combinatorial Chemistry
  • Cytotoxics (including Antimetabolites, Anthracyclin, Alkylating agents, Aurora kinases, Polo-like kinase, Toposisomerase inhibitors, Tubulin-binding compounds)
  • DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)
  • Drug Delivery
  • Drug Design

  • Drug Resistance and Modifiers

  • Drug Screening
  • Epigenetic modulators (HDAC Bromodomain modulators, EZH2)
  • Functional Genomics
  • Immune checkpoints
  • Molecular profiling
  • Molecular Targeted Agents
  • New agents for paediatric oncology
  • New drugs
  • New therapies in immuno-oncology
  • Novel clinical trial design
  • Oncolytic viruses and vaccination
  • Preclinical Models
  • Radiation Interactive Agents
  • Regulatory Affairs
  • Translational Studies
  • Tumour immunology and inflammation
  • Vaccine